Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy

Vanessa L. Gates, James E. Carey, Jeffry A. Siegel, Mark S. Kaminski, Richard L. Wahl

Research output: Contribution to journalArticle

Abstract

The expected effective dose equivalent to an individual from contact with 131l anti-B1 radioimmunotherapy (RIT) patients released immediately after therapeutic infusion was estimated. Methods: Effective dose equivalents were calculated retrospectively using data acquired on 46 patients treated with 131l anti-B1 RIT as inpatients. Effective dose equivalents to members of the public were estimated using the method published in the Nuclear Regulatory Commission (NRC) Regulatory Guide 8.39, assuming the administered activity, the patient-specific effective half-life, the 0.25 occupancy factor, and no photon attenuation. Effective dose equivalents also were estimated using ionization chamber dose rates, measured immediately after therapeutic infusion and integrated to total decay based on the measured effective half-life. Results: For the whole-body treatment absorbed dose limit of 75 cGy (75 rad), the administered 131l activity ranged from 2.1 to 6.5 GBq (56 to 175 mCi), and the measured dose rate at 1 m ranged from 70 to 190 μSv/hr (7 to 19 mrem/hr). The total-body effective hafl-life for these patients ranged from ~40 to 88 hr. Using the NRC method and not accounting for the attenuation of photons, the mean dose equivalent to the public exposed to an 131l anti-B1 patient discharged without hospitalization was 4.9 ± 0.9 mSv (490 ± 90 mrem). The range was 3.2-6.6 mSv (320 to 660 mrem), where 48% of patients would deliver a dose to another individual that is 131l should be feasible for all patients under current NRC regulations. Implementing outpatient RIT should make the therapy more widely available and more convenient and should lower patient care costs without exceeding accepted limits for public exposure to radiation.

Original languageEnglish (US)
Pages (from-to)1230-1236
Number of pages7
JournalJournal of Nuclear Medicine
Volume39
Issue number7
StatePublished - Jul 1998
Externally publishedYes

Fingerprint

Radioimmunotherapy
Iodine
Outpatients
Photons
Therapeutics
Half-Life
Inpatients
Patient Care
Hospitalization
Costs and Cost Analysis

Keywords

  • Iodine- 131 therapy
  • Nuclear Regulatory Commission
  • Patient release
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Gates, V. L., Carey, J. E., Siegel, J. A., Kaminski, M. S., & Wahl, R. L. (1998). Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. Journal of Nuclear Medicine, 39(7), 1230-1236.

Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. / Gates, Vanessa L.; Carey, James E.; Siegel, Jeffry A.; Kaminski, Mark S.; Wahl, Richard L.

In: Journal of Nuclear Medicine, Vol. 39, No. 7, 07.1998, p. 1230-1236.

Research output: Contribution to journalArticle

Gates, VL, Carey, JE, Siegel, JA, Kaminski, MS & Wahl, RL 1998, 'Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy', Journal of Nuclear Medicine, vol. 39, no. 7, pp. 1230-1236.
Gates VL, Carey JE, Siegel JA, Kaminski MS, Wahl RL. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. Journal of Nuclear Medicine. 1998 Jul;39(7):1230-1236.
Gates, Vanessa L. ; Carey, James E. ; Siegel, Jeffry A. ; Kaminski, Mark S. ; Wahl, Richard L. / Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. In: Journal of Nuclear Medicine. 1998 ; Vol. 39, No. 7. pp. 1230-1236.
@article{e3ab304fe54a46bd9f83dd51539e9890,
title = "Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy",
abstract = "The expected effective dose equivalent to an individual from contact with 131l anti-B1 radioimmunotherapy (RIT) patients released immediately after therapeutic infusion was estimated. Methods: Effective dose equivalents were calculated retrospectively using data acquired on 46 patients treated with 131l anti-B1 RIT as inpatients. Effective dose equivalents to members of the public were estimated using the method published in the Nuclear Regulatory Commission (NRC) Regulatory Guide 8.39, assuming the administered activity, the patient-specific effective half-life, the 0.25 occupancy factor, and no photon attenuation. Effective dose equivalents also were estimated using ionization chamber dose rates, measured immediately after therapeutic infusion and integrated to total decay based on the measured effective half-life. Results: For the whole-body treatment absorbed dose limit of 75 cGy (75 rad), the administered 131l activity ranged from 2.1 to 6.5 GBq (56 to 175 mCi), and the measured dose rate at 1 m ranged from 70 to 190 μSv/hr (7 to 19 mrem/hr). The total-body effective hafl-life for these patients ranged from ~40 to 88 hr. Using the NRC method and not accounting for the attenuation of photons, the mean dose equivalent to the public exposed to an 131l anti-B1 patient discharged without hospitalization was 4.9 ± 0.9 mSv (490 ± 90 mrem). The range was 3.2-6.6 mSv (320 to 660 mrem), where 48{\%} of patients would deliver a dose to another individual that is 131l should be feasible for all patients under current NRC regulations. Implementing outpatient RIT should make the therapy more widely available and more convenient and should lower patient care costs without exceeding accepted limits for public exposure to radiation.",
keywords = "Iodine- 131 therapy, Nuclear Regulatory Commission, Patient release, Radioimmunotherapy",
author = "Gates, {Vanessa L.} and Carey, {James E.} and Siegel, {Jeffry A.} and Kaminski, {Mark S.} and Wahl, {Richard L.}",
year = "1998",
month = "7",
language = "English (US)",
volume = "39",
pages = "1230--1236",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy

AU - Gates, Vanessa L.

AU - Carey, James E.

AU - Siegel, Jeffry A.

AU - Kaminski, Mark S.

AU - Wahl, Richard L.

PY - 1998/7

Y1 - 1998/7

N2 - The expected effective dose equivalent to an individual from contact with 131l anti-B1 radioimmunotherapy (RIT) patients released immediately after therapeutic infusion was estimated. Methods: Effective dose equivalents were calculated retrospectively using data acquired on 46 patients treated with 131l anti-B1 RIT as inpatients. Effective dose equivalents to members of the public were estimated using the method published in the Nuclear Regulatory Commission (NRC) Regulatory Guide 8.39, assuming the administered activity, the patient-specific effective half-life, the 0.25 occupancy factor, and no photon attenuation. Effective dose equivalents also were estimated using ionization chamber dose rates, measured immediately after therapeutic infusion and integrated to total decay based on the measured effective half-life. Results: For the whole-body treatment absorbed dose limit of 75 cGy (75 rad), the administered 131l activity ranged from 2.1 to 6.5 GBq (56 to 175 mCi), and the measured dose rate at 1 m ranged from 70 to 190 μSv/hr (7 to 19 mrem/hr). The total-body effective hafl-life for these patients ranged from ~40 to 88 hr. Using the NRC method and not accounting for the attenuation of photons, the mean dose equivalent to the public exposed to an 131l anti-B1 patient discharged without hospitalization was 4.9 ± 0.9 mSv (490 ± 90 mrem). The range was 3.2-6.6 mSv (320 to 660 mrem), where 48% of patients would deliver a dose to another individual that is 131l should be feasible for all patients under current NRC regulations. Implementing outpatient RIT should make the therapy more widely available and more convenient and should lower patient care costs without exceeding accepted limits for public exposure to radiation.

AB - The expected effective dose equivalent to an individual from contact with 131l anti-B1 radioimmunotherapy (RIT) patients released immediately after therapeutic infusion was estimated. Methods: Effective dose equivalents were calculated retrospectively using data acquired on 46 patients treated with 131l anti-B1 RIT as inpatients. Effective dose equivalents to members of the public were estimated using the method published in the Nuclear Regulatory Commission (NRC) Regulatory Guide 8.39, assuming the administered activity, the patient-specific effective half-life, the 0.25 occupancy factor, and no photon attenuation. Effective dose equivalents also were estimated using ionization chamber dose rates, measured immediately after therapeutic infusion and integrated to total decay based on the measured effective half-life. Results: For the whole-body treatment absorbed dose limit of 75 cGy (75 rad), the administered 131l activity ranged from 2.1 to 6.5 GBq (56 to 175 mCi), and the measured dose rate at 1 m ranged from 70 to 190 μSv/hr (7 to 19 mrem/hr). The total-body effective hafl-life for these patients ranged from ~40 to 88 hr. Using the NRC method and not accounting for the attenuation of photons, the mean dose equivalent to the public exposed to an 131l anti-B1 patient discharged without hospitalization was 4.9 ± 0.9 mSv (490 ± 90 mrem). The range was 3.2-6.6 mSv (320 to 660 mrem), where 48% of patients would deliver a dose to another individual that is 131l should be feasible for all patients under current NRC regulations. Implementing outpatient RIT should make the therapy more widely available and more convenient and should lower patient care costs without exceeding accepted limits for public exposure to radiation.

KW - Iodine- 131 therapy

KW - Nuclear Regulatory Commission

KW - Patient release

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0031867028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031867028&partnerID=8YFLogxK

M3 - Article

C2 - 9669400

AN - SCOPUS:0031867028

VL - 39

SP - 1230

EP - 1236

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -